Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated February 1, 2018, reports the completion of the subsequent offering period for a tender offer to acquire Advanced Accelerator Applications S.A. (AAA). The filing serves as a notification of a material corporate event rather than a periodic financial report.
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, or margin data. It references historical 2017 full-year figures in the "About Novartis" section:
- 2017 Net Sales: USD 49.1 billion
- 2017 R&D Expenditure: Approximately USD 9.0 billion
- Workforce: Approximately 122,000 full-time-equivalent associates
Regarding the tender offer transaction:
- Offer Price: USD 41.00 per Ordinary Share (USD 82.00 per ADS)
- Shares Tendered: 95,127,753 Ordinary Shares (including ADSs)
- Ownership Acquired: Approximately 98.7% of all outstanding Ordinary Shares
Material Changes
The primary material change is the successful conclusion of the tender offer for AAA. Novartis Groupe France S.A. accepted for payment all shares validly tendered during both the initial and subsequent offering periods, which expired on January 31, 2018. This results in Novartis controlling approximately 98.7% of AAA's outstanding shares.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the potential completion of the acquisition. Management notes that actual results may vary due to significant risks, including:
- Regulatory actions or delays.
- Government regulation generally.
- Uncertainties regarding actual or potential legal proceedings related to the acquisition.
Novartis explicitly states there is no guarantee the acquisition will be completed as proposed or at any particular time.
Investor Verification Checklist
- Verify the final closing status of the AAA acquisition and any remaining regulatory approvals required.
- Review the Tender Offer Statement on Schedule TO and Solicitation/Recommendation Statement on Schedule 14D-9 filed with the SEC for detailed terms.
- Monitor for potential legal proceedings or regulatory delays that could impact the finalization of the deal.
- Confirm the integration timeline for AAA into Novartis's oncology portfolio.